Prognostic factors for short-term survival of cats that experienced postattenuation neurologic signs after surgical attenuation of single congenital portosystemic shunts

Le résumé fourni par la source

Objective: To report 30-day survival of cats that experienced postattenuation neurologic signs (PANS) after surgical attenuation of a single congenital portosystemic shunt (cPSS), and to investigate prognostic factors for short-term survival. Study design: Multi-institutional retrospective study. Sample population: A total of 59 cats with cPSS that experienced PANS. Methods: The medical records of 10 institutions were retrospectively reviewed to identify cats that underwent cPSS attenuation from January 1, 2010 through June 30, 2023 and developed PANS within 7 days postoperatively. Exclusion criteria were cats with arteriovenous malformation and cats lost-to-follow-up prior to 30 days. Logistic regression identified factors associated with 30-day survival. Odds Ratios (OR) and 95% CIs were calculated. Results: A total of 46 (78.0%) PANS-affected cats survived to 30 days. A total of 13 (50.0%) of 26 cats that experienced postattenuation seizures (PAS) survived to 30 days, with most non-surviving cats experiencing generalized PAS. Cats that experienced PAS (p <.01, OR: 0.015, 95% CI: <0.001–0.281) and treatment of PANS with propofol (p <.01, OR: 0.112, 95% CI: 0.022–0.569) were associated with decreased odds of 30-day survival. Conclusion: Most cats that experienced PANS survived to 30 days; however, short-term survival rate was worse for cats that experienced PAS. Clinical significance: The prognosis for cats that experience PANS is generally good but experiencing PAS and requiring treatment with propofol are negative prognostic factors.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.